title: A polymorphism in the regulatory region of PRNP is associated with increased risk of sporadic Creutzfeldt-Jakob disease.
abstract: BACKGROUND
  Creutzfeldt-Jakob disease (CJD) is a rare transmissible neurodegenerative disorder. An important determinant for CJD risk and phenotype is the M129V polymorphism of the human prion protein gene (PRNP), but there are also other coding and non-coding polymorphisms inside this gene.
  
  
  METHODS
  We tested whether three non-coding polymorphism located inside the PRNP regulatory region (C-101G, G310C and T385C) were associated with risk of CJD and with age at onset in a United Kingdom population-based sample of 131 sporadic CJD (sCJD) patients and 194 controls.
  
  
  RESULTS
  We found no disease association for either PRNP C-101G or PRNP T385C. Although the crude analysis did not show a significant association between PRNP G310C and sCJD (OR: 1.5; 95%CI = 0.7 to 2.9), after adjusting by PRNP M129V genotype, it resulted that being a C allele carrier at PRNP G310C was significantly (p = 0.03) associated with a 2.4 fold increased risk of developing sCJD (95%CI = 1.1 to 5.4). Additionally, haplotypes carrying PRNP 310C coupled with PRNP 129M were significantly overrepresented in patients (p = 0.02) compared to controls. Cases of sCJD carrying a PRNP 310C allele presented at a younger age (on average 8.9 years younger than those without this allele), which was of statistical significance (p = 0.05). As expected, methionine and valine homozygosity at PRNP M129V increased significantly the risk of sCJD, alone and adjusted by PRNP G310C (OR MM/MV = 7.3; 95%CI 3.9 to 13.5 and OR VV/MV = 4.0; 95%CI 1.7 to 9.3).
  
  
  CONCLUSIONS
  Our findings support the hypothesis that genetic variations in the PRNP promoter may have a role in the pathogenesis of sCJD.
authors: Neurology Department, University Hospital Marqués de Valdecilla and CIBERNED, Santander, Spain.
authors: Pascual
authors: P
authors: Sanchez-Juan
authors: Matthew T
authors: MT
authors: Bishop
authors: Esther A
authors: EA
authors: Croes
authors: Richard Sg
authors: RS
authors: Knight
authors: Robert G
authors: RG
authors: Will
authors: Cornelia M
authors: CM
authors: van Duijn
authors: Jean C
authors: JC
authors: Manson
references: Clin Lab Med. 2003 Mar;23(1):87-108
references: 12733426
references: BMC Genet. 2007 Apr 16;8:15
references: 17437640
references: J Biol Chem. 1999 Jan 1;274(1):3-6
references: 9867802
references: Ann Neurol. 1998 Jan;43(1):32-40
references: 9450766
references: Science. 1992 Oct 30;258(5083):806-8
references: 1439789
references: Wkly Epidemiol Rec. 1998 Nov 20;73(47):361-5
references: 9844549
references: Lancet Neurol. 2009 Jan;8(1):57-66
references: 19081515
references: Lancet. 1999 May 15;353(9165):1673-4
references: 10335789
references: J Neurol. 2007 Jul;254(7):901-6
references: 17385081
references: Neurology. 2009 Jun 9;72(23):1994-2001
references: 19506221
references: J Biol Chem. 2005 Nov 11;280(45):37408-14
references: 16141216
references: Ann Neurol. 1999 Aug;46(2):224-33
references: 10443888
references: Brain. 2006 Sep;129(Pt 9):2278-87
references: 16816392
references: Proc Natl Acad Sci U S A. 2001 May 22;98(11):6279-83
references: 11353827
references: Neuron. 1991 Jul;7(1):59-68
references: 1676894
references: Neurology. 2006 Aug 22;67(4):637-43
references: 16924018
references: Neurodegeneration. 1994 Dec;3(4):331-40
references: 7842304
references: BMJ. 1997 Aug 16;315(7105):389-95
references: 9277601
references: Neurosci Lett. 2007 Jan 16;411(3):163-7
references: 17134829
references: Gene. 2002 Apr 17;288(1-2):139-46
references: 12034503
references: Acta Neurol Scand. 2003 Nov;108(5):374-8
references: 14616310
references: Ann Neurol. 2004 Nov;56(5):702-8
references: 15449324